v3.25.2
Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]        
Revenue [1] $ 444,328 $ 647,145 $ 927,977 $ 1,286,798
Depreciation and amortization expenses 23,141 29,870 47,199 59,373
Interest income (1,084) (1,370) (2,358) (3,920)
Interest expense 11,601 5,995 21,986 11,992
Gain (loss) from equity method investees (197) 1,700 (178) 1,394
Provision from income taxes (825) (238) 645 327
Change in tax receivables agreement liability 0 0 0 173
Net loss attributable to common shareholders of Evolent Health, Inc. - basic (51,090) (6,383) (123,340) (31,608)
Net loss attributable to common shareholders of Evolent Health, Inc. - diluted (51,090) (6,383) (123,340) (31,608)
Total compensation expense by financial statement line item 11,580 12,659 22,661 31,445
Severance and termination benefits        
Segment Reporting Information [Line Items]        
Restructuring charges 791 800 1,805 1,180
Cost of revenue        
Segment Reporting Information [Line Items]        
Total compensation expense by financial statement line item 1,050 1,207 1,707 2,212
Selling, general and administrative expenses        
Segment Reporting Information [Line Items]        
Total compensation expense by financial statement line item 10,530 11,452 20,954 29,233
Acquisition related costs 0 163 703 163
Repositioning costs 0 670 0 10,599
Reportable segment        
Segment Reporting Information [Line Items]        
Revenue 444,328 647,145 927,977 1,286,798
Medical expense and device costs 249,161 453,725 541,838 885,061
Cost of revenue excluding medical expense and device costs and other segment items 93,732 85,370 181,576 188,576
Selling, general and administrative expenses excluding other segment items 63,888 56,100 130,156 107,113
Depreciation and amortization expenses 23,141 29,870 47,199 59,373
Interest income (1,084) (1,370) (2,358) (3,920)
Interest expense 11,601 5,995 21,986 11,992
Gain (loss) from equity method investees (197) 1,700 (178) 1,394
Provision from income taxes (825) (238) 645 327
Change in tax receivables agreement liability 0 0 0 173
Other segment items 56,001 22,376 130,453 68,317
Net loss attributable to common shareholders of Evolent Health, Inc. - basic (51,090) (6,383) (123,340) (31,608)
Net loss attributable to common shareholders of Evolent Health, Inc. - diluted $ (51,090) $ (6,383) $ (123,340) $ (31,608)
[1] See Note 18 for amounts attributable to unconsolidated related parties included in these line items.